The newer hypoglycemic drugs, in particular incretins, are recommended for T2D patients with established CHD [6], and their potential beneficial pleiotropic effects on atherosclerotic plaque functionality and thus clinical outcome was recently documented in patients with a non-obstructive coronary artery stenosis non-ST-elevation myocardial infarction event [30]. Here, GCG is linked to coronary artery disorder.